#Mora calair trial#

Quality of life will be measured using the EuroQol EQ-5D at day 28, and the costs associated with hospitalization for AUGIB in the UK will be estimated. Clinical outcome measures include further bleeding, mortality, thromboembolic events, and infections.

Feasibility outcome measures include protocol adherence, recruitment rate, and evidence of selection bias. All clinicians will have the discretion to transfuse outside of the policy but will be asked to document the reasons for doing so.

In the liberal centers patients become eligible for transfusion once their hemoglobin is <10 g/dL. In the restrictive centers, patients become eligible for RBC transfusion when their hemoglobin is <8 g/dL.

#Mora calair trial#

Clinicians throughout each hospital will manage all eligible patients according to the transfusion policy for the 6-month trial recruitment period. The trial will take place in 6 UK hospitals, and each centre will be randomly allocated to a transfusion policy.

TRIGGER (Transfusion in Gastrointestinal Bleeding) is a pragmatic, cluster randomized trial which aims to evaluate the feasibility and safety of implementing a restrictive versus liberal RBC transfusion policy in adult patients admitted with AUGIB. Observational studies suggest an association between more liberal RBC transfusion and adverse patient outcomes, and a recent randomised trial reported increased further bleeding and mortality with a liberal transfusion policy. Acute upper gastrointestinal bleeding (AUGIB) is the commonest reason for hospitalization with hemorrhage in the UK and the leading indication for transfusion of red blood cells (RBCs).